Moleculin Biotech, Inc. (ticker: MBRX) recently announced encouraging preliminary results regarding Annamycin's effectiveness in treating relapsed or refractory acute myeloid leukemia (AML). These patients had previously shown disease progression following treatments with cytarabine (also known as Ara-C) and Venetoclax (VEN).
According to the company, Annamycin demonstrated efficacy against AML cell lines resistant to both Ara-C and Venetoclax in laboratory settings. The preclinical study noted several promising findings, including a lack of observed cardiotoxicity, improved targeting of organs, synergistic effects with Ara-C, and potential properties to reinforce immune memory.
The anti-leukemic potential of Annamycin, when combined with Ara-C, was further assessed using the TP53 null FLT3-ITD mutated syngeneic AML Turquoise2 model. This evaluation included analyzing the tumor presence in bone marrow, spleen, lungs, and liver using fluorescence imaging technology.
Looking ahead, the company is progressing Annamycin's development into a Phase 3 pivotal trial. This trial, named AnnAraC, is designed to treat AML patients who are resistant to or relapsed after initial induction therapy. The commencement of patient treatment is anticipated in the first quarter of 2025.
An abstract detailing these findings was published as part of the American Society of Hematology Annual Meeting. In response to these announcements, Moleculin's stock has experienced a 13.26 percent increase, reaching a current value of $2.72 on the Nasdaq.
The material has been provided by InstaForex Company -
www.instaforex.com
